Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aisa Pharma, Inc. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active for this portfolio. This count reflects the current workload for the company's patent applications in this specific field.
The prosecution is distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each of the 2 pending office actions is being reviewed by a different examiner in a different specialized unit of the patent office. The involvement of 2 distinct art units shows that the company's technology spans multiple technical classifications within the Biotechnology & Pharmaceuticals sector.
ELENISTE, PIERRE PAUL is the busiest examiner, with 1 busiest examiner pending office action. This examiner is responsible for 1 of the 2 total pending office actions. Because the workload is split between 2 distinct examiners, the company must manage different examination styles. Practitioners should prepare for the specific nuances of ELENISTE, PIERRE PAUL and the other assigned examiner to successfully navigate these 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836243 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | ELENISTE, PIERRE PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836243 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | ELENISTE, PIERRE PAUL | — |
| 18611280 | TREATMENT OF RAYNAUD'S DISEASE | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836243 | METHODS OF TREATING COMPLEX REGIONAL PAIN SYNDROME | ELENISTE, PIERRE PAUL | 1622 | §103§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18611280 | TREATMENT OF RAYNAUD'S DISEASE | HAVLIN, ROBERT H | 1626 | §103DP | Non-Final OA | — | Pending | Mar 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAisa Pharma, Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Pierre Paul Eleniste has the most, with 1 of Aisa Pharma, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
